CC BY-NC-ND 4.0 · Ann Natl Acad Med Sci 2023; 59(01): 021-026
DOI: 10.1055/s-0042-1760083
Original Article

Adherence and Cost Effectivity of Home-Based Prophylaxis Over Institutionalized Prophylaxis in Patients with Hemophilia

Anupam Dutta
1   Department of Medicine, Assam Medical College and Hospital, Dibrugarh, Assam, India
,
1   Department of Medicine, Assam Medical College and Hospital, Dibrugarh, Assam, India
,
Angshuman Boruah
1   Department of Medicine, Assam Medical College and Hospital, Dibrugarh, Assam, India
,
Arijit Das
1   Department of Medicine, Assam Medical College and Hospital, Dibrugarh, Assam, India
› Author Affiliations
Funding None.

Abstract

Purpose: Home-based prophylaxis in hemophilia facilitates the treatment of patients with hemophilia (PwH) at home resulting in an improved quality of life, experiencing less pain and greater flexibility in daily activities. This literature studies the cost effectivity and adherence to prophylaxis treatment after the implementation of home-based prophylaxis therapy in PwH registered under the Hemophilia Treatment Centre (HTC) of Assam Medical College and Hospital.

Materials and Methods: PwH and their parents were advised for self/home infusion after being trained by a medical professional for 6 months. Data were collected on the skip in prophylaxis treatment by PwH and their traveling cost to access the prophylaxis treatment before and after the implementation of home infusion, through questionnaire and telephonic interview.

Results: The mean number of days of skip in prophylaxis was significantly reduced from 25 (±11) to 4 (±2) days after implementation of home infusion. The mean transportation cost was also found to be significantly decreased from Rs. 3297 (±2251) to 440 (±279). Before home/self-infusion, 77% of the registered PwH were found to skip prophylaxis doses more than 12 times a year but after home infusion, no PwH were found to skip more than 12 doses a year.

Conclusion: Home therapy facilitates the PwH to strictly adhere to the prophylaxis regime significantly reducing the skipping of doses to be administered to the PwH. The risks of regular traveling and the burden of transportation expenditure to avail the prophylaxis treatment was also found to be reduced significantly.

Author's Contribution

All authors have substantive intellectual contributions to this study.


Anupam Dutta contributed to the planning and conducting the study.


Dipjyoti Boruah contributed to the collection of data and preparation of the manuscript.


Angshuman Boruah contributed to statistical analysis.


Arijit Das contributed to the collection of data.


Statement of Institutional Review Board Approval

Research of the following manuscript has been approved and recommended by Institutional Ethics Committee (H), Assam Medical College, Dibrugarh. (Reg. No. ECR/636/Inst/AS/2014) on September 22, 2021. For authentication, the document of recommendation by institutional ethics committee has been attached in the PDF format.


Supplementary Material



Publication History

Article published online:
06 February 2023

© 2023. National Academy of Medical Sciences (India). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Srivastava A, Brewer AK, Mauser-Bunschoten EP. et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19 (01) e1-e47
  • 2 Ergün S, Sülü E, Başbakkal Z. Supporting the need for home care by mothers of children with hemophilia. Home Healthc Nurse 2011; 29 (09) 530-538
  • 3 Teitel JM, Barnard D, Israels S, Lillicrap D, Poon MC, Sek J. Home management of haemophilia. Haemophilia 2004; 10 (02) 118-133
  • 4 Soucie JM, Symons IV J, Evatt B, Brettler D, Huszti H, Linden J. Hemophilia Surveillance System Project Investigators. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001; 7 (02) 198-206
  • 5 Rabiner SF, Telfer MC. Home transfusion for patients with hemophilia A. N Engl J Med 1970; 283 (19) 1011-1015
  • 6 Rodriguez-Merchan EC. The cost of hemophilia treatment: the importance of minimizing it without detriment to its quality. Expert Rev Hematol 2020; 13 (03) 269-274
  • 7 Ekert H, Moorehead M, Williamson G. Home treatment of haemophilia. A follow-up study. Med J Aust 1981; 2 (01) 21-23
  • 8 Levine PH, Britten AF. Supervised patient-management of hemophilia. A study of 45 patients with hemophilia A and B. Ann Intern Med 1973; 78 (02) 195-201
  • 9 Rabiner SF, Telfer MC, Fajardo R. Home transfusions of hemophiliacs. JAMA 1972; 221 (08) 885-887
  • 10 Ingram GI, Dykes SR, Creese AL. et al. Home treatment in haemophilia: clinical, social and economic advantages. Clin Lab Haematol 1979; 1 (01) 13-27
  • 11 Rizza CR, Spooner RJ. Home treatment of haemophilia and Christmas disease: five years' experience. Br J Haematol 1977; 37 (01) 53-66
  • 12 Szucs TD, Offner A, Kroner B, Giangrande P, Berntorp E, Schramm W. The European Socioeconomic Study Group. Resource utilisation in haemophiliacs treated in Europe: results from the European Study on Socioeconomic Aspects of Haemophilia Care. Haemophilia 1998; 4 (04) 498-501
  • 13 du Treil S, Rice J, Leissinger CA. Quantifying adherence to treatment and its relationship to quality of life in a well-characterized haemophilia population. Haemophilia 2007; 13 (05) 493-501
  • 14 Collins PW, Blanchette VS, Fischer K. et al; rAHF-PFM Study Group. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7 (03) 413-420
  • 15 Fischer K, Van Der Bom JG, Prejs R. et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia 2001; 7 (06) 544-550
  • 16 van Os SB, Troop NA, Sullivan KR, Hart DP. Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a quantitative study with patients. PLoS One 2017; 12 (01) e0169880
  • 17 Santagostino E, Mancuso ME, Tripodi A. et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8 (04) 737-743
  • 18 Khair K, Lawrence K, Butler R, O'Shea E, Christie BA. Assessment of treatment practice patterns for severe hemophilia A: a global nurse perspective. Acta Haematol 2008; 119 (02) 115-123
  • 19 Thornburg CD, Duncan NA. Treatment adherence in hemophilia. Patient Prefer Adherence 2017; 11: 1677-1686
  • 20 Dutta A, Boruah D, Dutta TS. et al. Improvement in school absence after factor replacement in students with haemophilia in Upper Assam, India. The Journal of Haemophilia Practice 2020; 7 (01) 136-142
  • 21 Lazerson J. Hemophilia home transfusion program: effect on school attendance. J Pediatr 1972; 81 (02) 330-332
  • 22 Strawczynski H, Stachewitsch A, Morgenstern G, Shaw ME. Delivery of care to hemophilic children: home care versus hospitalization. Pediatrics 1973; 51 (06) 986-991